Superstring Capital Administration disclosed a brand new place in Vir Biotechnology (NASDAQ:VIR)buying 730,548 shares within the first quarter. The estimated transaction worth was $5.82 million primarily based on quarterly common pricing.
What occurred
Based on a filing with the U.S. Securities and Exchange Commission dated Could 14, 2026, Superstring Capital established a brand new place in Vir Biotechnology with 730,548 shares bought. The estimated transaction worth was $5.82 million, primarily based on the imply unadjusted closing value for the primary quarter of 2026. The fund’s quarter-end place in Vir Biotechnology was valued at $6.55 million, reflecting each buying and selling exercise and value appreciation.
What else to know
-
Prime holdings following the submitting:
-
NASDAQ: SMMT: $16.93 million (12.1% of AUM)
-
NASDAQ: IMVT: $8.88 million (6.3% of AUM)
-
NASDAQ: COGT: $8.67 million (6.2% of AUM)
-
NASDAQ: SVRA: $8.66 million (6.2% of AUM)
-
NASDAQ: URGN: $6.96 million (5.0% of AUM)
-
-
As of Friday, Vir Biotechnology shares have been priced at $9.19, up 99% over the previous yr and effectively outperforming the S&P 500, which is as a substitute up about 28% in the identical interval.
Firm Overview
|
Metric |
Worth |
|---|---|
|
Income (TTM) |
$64.7 million |
|
Internet Revenue (TTM) |
($442.7 million) |
|
Worth (as of Friday) |
$9.19 |
|
One-Yr Worth Change |
99% |
Firm Snapshot
-
Vir develops monoclonal antibodies and RNA-based therapeutics concentrating on infectious illnesses, together with COVID-19, hepatitis B, influenza A, and HIV.
-
The agency generates income primarily by way of product gross sales, licensing agreements, and strategic collaborations with pharmaceutical and biotechnology companions.
-
It serves healthcare suppliers, authorities companies, and world well being organizations targeted on infectious illness prevention and therapy.
Vir Biotechnology, Inc. is a commercial-stage biotechnology firm specializing within the growth of revolutionary immunology-based therapies for critical infectious illnesses. The corporate leverages collaborations with main world companions to advance its pipeline and develop market attain. Vir’s technique facilities on addressing unmet medical wants by way of scientific innovation and strategic alliances within the healthcare sector.
What this transaction means for buyers
This buy appears like a guess on catalysts fairly than present monetary outcomes. Vir stays unprofitable, however Superstring seems to be positioning for what could possibly be a pivotal stretch of medical and partnership-driven developments over the subsequent 18 months.
The corporate entered the second quarter with a robust stability sheet, reporting $809.3 million in money, money equivalents, and investments, whereas additionally anticipating to obtain a further $315 million from its not too long ago accomplished Astellas collaboration and associated fairness funding. Simply as vital, Vir’s pipeline continues to advance. Administration highlighted encouraging Section 2 knowledge for its persistent hepatitis delta program, with 88% of evaluated sufferers reaching undetectable virus ranges by way of Week 96. The corporate additionally expects Section 3 knowledge from its lead hepatitis delta research within the fourth quarter of 2026.
In the meantime, Vir’s oncology platform is gaining momentum. The corporate not too long ago closed its prostate most cancers partnership with Astellas, dosed the primary affected person in enlargement cohorts for VIR-5500, and is concentrating on pivotal Section 3 trials starting in 2027.
For long-term buyers, the story stays excessive danger and extremely depending on medical execution. However with a considerable money runway into the second half of 2028 and several other main knowledge readouts forward, this appears much less like a balance-sheet survival story and extra like an organization approaching a collection of probably value-defining milestones.
